Oculis’ (OCS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Oculis (NASDAQ:OCS) in a report released on Monday,Benzinga reports. The brokerage currently has a $30.00 price target on the stock.

Oculis Stock Performance

Oculis stock opened at $15.99 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.27 and a quick ratio of 5.27. Oculis has a 1-year low of $9.60 and a 1-year high of $18.00. The firm has a market capitalization of $647.66 million, a P/E ratio of -8.28 and a beta of -0.16. The company’s 50-day moving average is $14.09 and its 200 day moving average is $12.64.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Tuesday, August 27th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.13). The firm had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $0.28 million. Oculis had a negative return on equity of 71.90% and a negative net margin of 8,043.28%. Research analysts forecast that Oculis will post -2.19 EPS for the current year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.